7,430.50

+28.50

+0.39%

51,748.00

+363.00

+0.71%

27,096.75

+11.50

+0.04%

Russell 2000 Futures

2,788.20

+27.70

+1.00%

4.8590

+0.0220

+0.45%

24.15

-1.49

-5.82%

4,103.40

+28.50

+0.70%

74,577.96

-1,240.72

-1.64%

Crude Oil Dec 26

89.69

-1.14

-1.26%

US Private Equity

10,772.76

+11.83

+0.11%

Frankfurt - Delayed Quote EUR

Ultragenyx Pharmaceutical Inc. (UP0.F)

13.77 +0.24 (+1.74%)

As of 8:07:13 AM GMT+1. Market Open.

Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down

BioPharma Dive 2d ago

HIMS

LLY

ALNY
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

GlobeNewswire 3d ago

RARE
Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...

GuruFocus.com 3d ago

RARE
Ultragenyx Pharmaceutical (RARE) Stock Looks Fairly Valued After Upcoming FDA Decisions

Simply Wall St. 4d ago

RARE
Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Motley Fool 4d ago

RARE
Ultragenyx Pharmaceutical Inc. Q3 2026 Earnings Call Summary

Moby 4d ago

NVDA

RARE
Gene Therapy Launches Could Be A Game Changer For Ultragenyx Stock (RARE)

Simply Wall St. 4d ago

RARE
Ultragenyx Pharmaceutical (RARE) Recasts The Story After FDA Approvals As Valuation Debate Builds

Simply Wall St. 4d ago

RARE
What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

MarketBeat 5d ago

RARE
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates

Zacks 5d ago

RARE

STLN
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics

Zacks 5d ago

RARE
Ultragenyx: Q3 Earnings Snapshot

Associated Press 5d ago

RARE

Mobilize your Website

View Site in Mobile | Classic

Share by: